Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04309656 · ClinicalTrials.gov registry record · Phase 1
Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
A Phase 1 study of Multi-drug Resistant Tuberculosis, sponsored by Global Alliance for TB Drug Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04309656 is a Phase 1 study of Multi-drug Resistant Tuberculosis that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04309656, a Phase 1 study of Multi-drug Resistant Tuberculosis, has completed, sponsored by Global Alliance for TB Drug Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-dose, open-label, randomized, four-period, four-treatment, crossover study in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Pretomanid
Study Locations (1)
Texas
- Worldwide Clinical Trials Early Phase Services, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2020-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04309656
The ClinicalTrials.gov registry entry for NCT04309656 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Global Alliance for TB Drug Development, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multi-drug Resistant Tuberculosis appearing as the primary indexed condition, and to 1 intervention - of which Pretomanid is the first listed.
NCT04309656 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04309656 about?
NCT04309656 is a clinical study titled "Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid". This is a single-dose, open-label, randomized, four-period, four-treatment, crossover study in healthy adult subjects.
What is the current status of trial NCT04309656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-01-14. Estimated completion is 2020-02-28.
What conditions does trial NCT04309656 study?
This clinical trial studies the following conditions: Multi-drug Resistant Tuberculosis.
What interventions are being tested in trial NCT04309656?
The interventions under investigation include: Pretomanid (DRUG).
Who is sponsoring clinical trial NCT04309656?
This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04309656 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multi-drug Resistant Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.